Targeted exhaled breath analysis for detection of Pseudomonas aeruginosa in cystic fibrosis patients
- PMID: 34016557
- DOI: 10.1016/j.jcf.2021.04.015
Targeted exhaled breath analysis for detection of Pseudomonas aeruginosa in cystic fibrosis patients
Abstract
Background: Pseudomonas aeruginosa (PA) is an important respiratory pathogen for cystic fibrosis (CF) patients. Routine microbiology surveillance is time-consuming, and is best performed on expectorated sputum. As alternative, volatile organic compounds (VOCs) may be indicative of PA colonisation. In this study, we aimed to identify VOCs associated with PA in literature and perform targeted exhaled breath analysis to recognize PA positive CF patients non-invasively.
Methods: This study consisted of 1) a literature review to select VOCs of interest, and 2) a cross-sectional CF study. Definitions used: A) PA positive, PA culture at visit/chronically; B) PA free, no PA culture in ≥12 months. Exhaled VOCs were identified via quadrupole MS. The primary endpoint was the area under the receiver operating characteristics curve (AUROCC) of individual VOCs as well as combined VOCs against PA culture.
Results: 241 VOCs were identified in literature, of which 56 were further evaluated, and 13 could be detected in exhaled breath in our cohort. Exhaled breath of 25 pediatric and 28 adult CF patients, PA positive (n=16) and free (n=28) was available. 3/13 VOCs were significantly (p<0.05) different between PA groups in children; none were in adults. Notably, a composite model based on 5 or 1 VOC(s) showed an AUROCC of 0.86 (CI 0.71-1.0) and 0.87 (CI 0.72-1.0) for adults and children, respectively.
Conclusions: Targeted VOC analysis appears to discriminate children and adults with and without PA positive cultures with clinically acceptable sensitivity values.
Keywords: Cystic fibrosis; Exhaled biomarkers; Pseudomonas aeruginosa; VOC.
Copyright © 2021. Published by Elsevier B.V.
Conflict of interest statement
Declaration of Competing Interests AHM and PB are supported by an innovation grant from Vertex Pharmaceuticals B.V. PJS is scientific advisor and has a formally inconsiderable interest in the SME Breathomix AHM reports grants and personal fees from GSK, Boehringer Ingelheim, and AstraZeneca, and grants from Chiesi, outside the submitted work.
Similar articles
-
Do linear logistic model analyses of volatile biomarkers in exhaled breath of cystic fibrosis patients reliably indicate Pseudomonas aeruginosa infection?J Breath Res. 2016 Aug 17;10(3):036013. doi: 10.1088/1752-7155/10/3/036013. J Breath Res. 2016. PMID: 27532768
-
Exhaled breath profiles to detect lung infection with Staphylococcus aureus in children with cystic fibrosis.J Cyst Fibros. 2023 Sep;22(5):888-893. doi: 10.1016/j.jcf.2023.02.010. Epub 2023 Feb 26. J Cyst Fibros. 2023. PMID: 36849333
-
Hydrogen cyanide concentrations in the breath of adult cystic fibrosis patients with and without Pseudomonas aeruginosa infection.J Breath Res. 2013 Jun;7(2):026010. doi: 10.1088/1752-7155/7/2/026010. Epub 2013 May 17. J Breath Res. 2013. PMID: 23680696
-
Hydrogen cyanide, a volatile biomarker of Pseudomonas aeruginosa infection.J Breath Res. 2013 Dec;7(4):044001. doi: 10.1088/1752-7155/7/4/044001. Epub 2013 Nov 28. J Breath Res. 2013. PMID: 24287489 Review.
-
Exhaled volatile organic compounds associated with chronic obstructive pulmonary disease exacerbations-a systematic review and validation.J Breath Res. 2025 Mar 11;19(2). doi: 10.1088/1752-7163/adba06. J Breath Res. 2025. PMID: 39999477
Cited by
-
Identification of Exhaled Metabolites in Children with Cystic Fibrosis.Metabolites. 2022 Oct 17;12(10):980. doi: 10.3390/metabo12100980. Metabolites. 2022. PMID: 36295881 Free PMC article.
-
New methods to detect bacterial or viral infections in patients with chronic obstructive pulmonary disease.Expert Rev Respir Med. 2024 Sep;18(9):693-707. doi: 10.1080/17476348.2024.2396413. Epub 2024 Aug 29. Expert Rev Respir Med. 2024. PMID: 39175157 Review.
-
Machine Learning Model Discriminate Ischemic Heart Disease Using Breathome Analysis.Biomedicines. 2024 Dec 11;12(12):2814. doi: 10.3390/biomedicines12122814. Biomedicines. 2024. PMID: 39767720 Free PMC article.
-
Uncovering Non-Invasive Biomarkers in Paediatric Severe Acute Asthma Using Targeted Exhaled Breath Analysis.Metabolites. 2025 Apr 3;15(4):247. doi: 10.3390/metabo15040247. Metabolites. 2025. PMID: 40278376 Free PMC article.
-
Pseudomonas aeruginosa in the Cystic Fibrosis Lung.Adv Exp Med Biol. 2022;1386:347-369. doi: 10.1007/978-3-031-08491-1_13. Adv Exp Med Biol. 2022. PMID: 36258079
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials